Hennion & Walsh Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Hennion & Walsh Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,305	Closed	-$543K	–	820
2023 Q1	$543K	Sell	9,305 -319	-3%	-$15.7K	0.03%	492
2022 Q4	$491K	Sell	9,624 -8,804	-48%	-$610K	0.03%	507
2022 Q3	$1.51M	Sell	18,428 -683	-4%	-$51K	0.1%	244
2022 Q2	$1.29M	Sell	19,111 -6,611	-26%	-$606K	0.08%	261
2022 Q1	$2.84M	Sell	25,722 -524	-2%	-$65.3K	0.15%	180
2021 Q4	$2.53M	Sell	26,246 -919	-3%	-$91.6K	0.12%	208
2021 Q3	$2.37M	Buy	27,165 +2,112	+8%	+$219K	0.12%	220
2021 Q2	$3.88M	Buy	25,053 +7,255	+41%	+$1.05M	0.21%	125
2021 Q1	$2.81M	Buy	+17,798	New	+$3.75M	0.17%	172

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Hennion & Walsh Asset Management's KPTI Position: Q2 2023 in Review

Hennion & Walsh Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 9,305 shares — an estimated $543K sold.

Hennion & Walsh Asset Management first reported a position in KPTI in Q1 2021 and held it in 9 quarters. The position peaked at $3.88M in Q2 2021. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

Hennion & Walsh Asset Management reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
Hennion & Walsh Asset Management sold 9,305 Karyopharm Therapeutics shares in Q2 2023, an estimated $543K.
Hennion & Walsh Asset Management first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 9 quarters.
Hennion & Walsh Asset Management's Karyopharm Therapeutics position peaked at $3.88M in Q2 2021.
137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.